Entero Healthcare Solutions
1,140.70
+8.50(+0.75%)
Market Cap₹4,963.29 Cr
PE Ratio38.60
IndustryRetail
Company Performance:
1D+0.75%
1M+2.53%
6M-12.14%
1Y-26.39%
5Y-0.77%
View Company Insightsright
More news about Entero Healthcare Solutions
13Nov 25
Entero Healthcare Reports 21% Revenue Growth in Q2FY26, Expands MedTech Operations Through Acquisitions
Entero Healthcare Solutions Limited reported robust Q2FY26 results with 21% YoY revenue growth to Rs. 15,709.48 crore, 46% EBITDA growth to Rs. 621.00 crore, and 41% PAT growth to Rs. 366.00 crore. The company announced two strategic acquisitions in the MedTech segment: an 80% stake in Bioaide Technologies and a 51% stake in Anand Chemiceutics. These acquisitions are expected to generate Rs. 1,000.00 crore in annualized revenue and improve margins. Entero's customer base expanded to 85,300+ retail pharmacies and 2,800+ hospitals, with operations across 20 states in India.
 no imag found
13Nov 25
Entero Healthcare Solutions Promotes Abhitesh Kumar to Chief Growth Officer, Announces Strategic Acquisitions
Entero Healthcare Solutions has promoted Abhitesh Kumar to Chief Growth Officer. The company is acquiring an 80% stake in Bioaide Technologies for INR 31.13-36 Crore and a 51% stake in Anand Chemiceutics for INR 210-230 Crore. Entero's Q2 FY2026 revenue increased to INR 15,709.48 million, with profit rising to INR 366.00 million. The company also allotted 2,030 equity shares under its Employee Stock Option Plan 2023.
 no imag found
13Nov 25
Entero Healthcare Solutions Reports Strong Q2 Results, Announces Strategic Acquisitions
Entero Healthcare Solutions Limited reported robust financial results for Q2 and H1 FY26. Q2 revenue increased to Rs. 15,709.48 crore, with PAT rising to Rs. 366.00 crore. H1 FY26 saw revenue growth of 24.1% YoY to Rs. 29,747.67 crore, EBITDA growth of 30.8% to Rs. 1,126.36 crore, and PAT growth of 43.5% to Rs. 668.32 crore. The company announced acquisitions of an 80% stake in Bioaide Technologies and a 51% stake in Anand Chemiceutics to strengthen its market position. Other developments include allotment of employee stock options, appointment of a new Chief Growth Officer, and utilization of IPO funds.
 no imag found
13Nov 25
Entero Healthcare Solutions Reports Strong Q2 FY26 Growth, Announces Strategic Acquisitions
Entero Healthcare Solutions reported robust financial performance for Q2 FY26 with consolidated revenue of Rs. 15,709.48 crore and profit after tax of Rs. 366.00 crore. The company announced two strategic acquisitions: an 80% stake in Bioaide Technologies and a 51% stake in Anand Chemiceutics, to expand its distribution network. EBITDA improved to Rs. 777.21 crore with a margin of 4.95%. The company also reported successful utilization of IPO proceeds and appointed Mr. Abhitesh Kumar as Chief Growth Officer.
 no imag found
12Nov 25
Entero Healthcare Solutions Reports Strong Q2 Growth, Plans Strategic Acquisitions
Entero Healthcare Solutions posted robust Q2 FY25-26 results with a 33.90% increase in net profit to Rs 316.00 million and 20.80% revenue growth to Rs 15.71 billion. The company plans to acquire an 80% stake in Bioaide Technologies and a 51% stake in Anand Chemiceutics to expand its market reach and product portfolio in healthcare distribution. Abhitesh Kumar has been elevated to Chief Growth Officer to drive expansion plans.
 no imag found
29Sept 25
Entero Healthcare Solutions Reshapes Portfolio: Sells Suprabhat Pharmaceutical, Eyes Majority Stake in Ace Cardiopathy
Entero Healthcare Solutions has announced two major transactions. The company will divest its entire 100% stake in Suprabhat Pharmaceutical Private Limited for up to INR 37,00,000, to be completed in FY 2025-26. Simultaneously, Entero will acquire a 60% stake in Ace Cardiopathy Solutions Private Limited, a medical devices distributor, for INR 59.30-77.10 crore. The acquisition is expected to be finalized by January 31, 2026. These moves aim to streamline operations and expand Entero's presence in the medical devices distribution sector.
 no imag found
13Aug 25
GIC Private Limited Reduces Stake in Entero Healthcare Solutions to 3.14%
The Government of Singapore (GOS), through GIC, has sold 9,846 equity shares of Entero Healthcare Solutions Limited on August 11, 2025. This transaction reduced GIC's shareholding from 3.16% to 3.14% of the company's total share capital. GIC's stake has been gradually decreasing since February 2024, when it held a 5.16% stake. The disclosure was made in compliance with SEBI regulations.
 no imag found
08Aug 25
Entero Healthcare Solutions Reports Q1 Results, Extends Pharma Acquisition Deadline
Entero Healthcare Solutions Limited reported robust Q1 financial results with consolidated revenue reaching ₹14,038.19 million and net profit of ₹302.32 million. The company acquired a 70% stake in Ramson Medical Distributors and increased its shareholding in Peerless Biotech to 76%. The deadline for acquiring equity shares in four pharma companies has been extended to November 30. Three non-operating subsidiaries were struck off during the quarter.
 no imag found
27May 25
Entero Healthcare Solutions Reports Strong Q4 Performance with Significant EBITDA and Profit Growth
Entero Healthcare Solutions announced impressive Q4 financial results. EBITDA surged 69.20% to ₹489.00 crore, with EBITDA margin improving to 3.65%. Consolidated net profit increased 22.40% to ₹257.00 crore. Revenue grew 29.60% to ₹13,400.00 crore. The company's performance demonstrates operational efficiency and strong market position in the healthcare sector.
 no imag found
19Mar 25
Entero Healthcare Solutions Expands Digital Footprint with Aayu Chemist and Medcords Acquisition
Entero Healthcare Solutions has acquired the Aayu Chemist app and Medcords platform from Medcords Healthcare as part of its new 'HealthEdge' programme. This initiative aims to digitally empower retail chemists across India with features like inventory management, expiry management, online store management, and financial support. The acquisition is expected to strengthen Entero's market position, which currently serves over 86,200 retail pharmacies and 3,200 hospitals across 492 districts in India.
 no imag found
06Mar 25
Entero Healthcare Solutions Boosts Stake in Getwell Medicare with ₹170 Crore Investment
Entero Healthcare Solutions Limited has increased its stake in subsidiary Getwell Medicare Solutions Private Limited from 85% to 95.20% through a ₹170 crore investment in equity shares on a rights basis. This strategic move expands Entero's shareholding from 68,00,000 to 2,38,00,000 equity shares, strengthening its position in the healthcare sector.
 no imag found
Entero Healthcare Solutions
1,140.70
+8.50
(+0.75%)
1 Year Returns:-26.39%
Industry Peers
Vijaypd Ceutical
63.30
(+12.93%)
Trimurthi
63.75
(+2.03%)